Record number of blockbusters predicted to hit the market in 2018

While there is plenty of doom and gloom about the current cost of developing drugs and  low returns on investment in R&D, a new report highlights that big-selling drugs are still set to enter the market in 2018, and in record numbers.

Clarivate Analytics’ Drugs to Watch report has identified 12 new drugs due to be launched this year that are forecast to achieve annual sales of $1 billion or more by 2022, which is more than any year since the analysis began in 2013.

The report is put together using the Cortellis database, which includes information gathered from diverse sources including drug pipelines, patents, clinical trials, chemistry, deals and company announcements.